Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 36,516 | 36,884 | 64,835 | 84,675 | 55,150 |
| Cost of Goods | 4,699 | 11,984 | 11,446 | 30,593 | 8,153 |
| Gross Profit | 31,817 | 24,900 | 53,389 | 54,082 | 46,997 |
| Operating Expenses | 30,383 | -11,807 | 38,129 | 8,936 | 42,435 |
| Operating Income | 2,133 | 37,691 | 15,706 | 45,739 | 4,715 |
| Interest Expense | 789 | 4,466 | 4,439 | 4,883 | 5,831 |
| Other Income | -10,488 | -15,344 | 3,992 | -7,555 | 6,880 |
| Pre-tax Income | -9,144 | 17,881 | 15,259 | 33,301 | 5,764 |
| Income Tax | 3,785 | 4,082 | 1,536 | 2,576 | -12,342 |
| Net Income Continuous | -12,929 | 13,799 | 13,723 | 30,725 | 18,106 |
| Net Income Discontinuous | -2,456 | N/A | N/A | N/A | N/A |
| Net Income | $-15,385 | $-5,416 | $13,723 | $30,725 | $18,106 |
| EPS Basic Total Ops | -0.91 | -0.32 | 0.82 | 1.84 | 1.10 |
| EPS Basic Continuous Ops | -0.77 | 0.82 | 0.82 | 1.84 | 1.10 |
| EPS Basic Discontinuous Ops | -0.15 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.91 | -0.33 | 0.80 | 1.79 | 1.05 |
| EPS Diluted Continuous Ops | -0.77 | 0.79 | 0.80 | 1.79 | 1.05 |
| EPS Diluted Discontinuous Ops | -0.15 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $16,154 | $54,434 | $32,145 | $62,147 | $22,874 |